Preview Mode Links will not work in preview mode

May 4, 2022

Join Daniel R. Goldstein, MD, Editor-in-Chief of JHLT, and the JHLT Digital Media Editors for two interviews with authors from the May issue of The Journal of Heart and Lung Transplantation. You’ll hear about the scientific journey of each of these authors as well as more about the work they’re publishing this month.

First, the editors speak with John Greenland, MD, PhD (pictured), from the University of California San Francisco, who is the first author of a paper entitled “Lung transplant recipients with idiopathic pulmonary fibrosis have impaired alloreactive immune responses.” Erika Lease, MD, interviews Dr. Greenland about his PhD journey, his dedication to research, and how he keeps clinical work from outcompeting his research tasks. He even shares some pearls of advice for aspiring physician-scientists before exploring his study, which investigates the role of telomere dysfunction on T-cell proliferation to donor antigens in patients who undergo lung transplantation for idiopathic pulmonary fibrosis (IDF).

Next, David Schibilsky, MD, and Marty Tam, MD, are in conversation with author Tamta Tkhilaishvili, MD, PhD (pictured), from the University of Rostock, on her study: “Bacteriophage therapy as a treatment option for complex cardiovascular implant infection: The German Heart Center Berlin experience.” Dr. Tkhilaishvili shares her journey through an interdisciplinary PhD, but also what it’s been like to earn a PhD in Germany without knowing the German language. It’s a fascinating international and multidisciplinary story! She also shares her work on treating implanted cardiovascular device infections using bacteriophage therapy, an innovative new management strategy.

Follow along in the May issue at, or, if you’re an ISHLT member, log in at  Don’t already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at for a free subscription, or subscribe today at

This episode of JHLT: The Podcast, but not the studies within, is sponsored by Bayer Pharmaceuticals.